CU20110232A7 - Inyección de diacetato de ipamorelin y soluciones de la infusión - Google Patents

Inyección de diacetato de ipamorelin y soluciones de la infusión

Info

Publication number
CU20110232A7
CU20110232A7 CU20110232A CU20110232A CU20110232A7 CU 20110232 A7 CU20110232 A7 CU 20110232A7 CU 20110232 A CU20110232 A CU 20110232A CU 20110232 A CU20110232 A CU 20110232A CU 20110232 A7 CU20110232 A7 CU 20110232A7
Authority
CU
Cuba
Prior art keywords
ipamorelin
injection
infusion solutions
diacetate
acetic acid
Prior art date
Application number
CU20110232A
Other languages
English (en)
Inventor
Roccardo Braglia
Helle Weibel
Daniel Beidler
Rubio Silvina Garcia
Original Assignee
Helsinn Therapeutics Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20110232(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Therapeutics Us Inc filed Critical Helsinn Therapeutics Us Inc
Publication of CU20110232A7 publication Critical patent/CU20110232A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Soluciones de la inyección y de la infusión de ipamorelin que tienen la siguiente composición: a) ipamorelin solubilizado por aproximadamente dos equivalentes molares de ácido acético (diacetato de ipamorelin), en una cantidad a partir de 0.001 al 20%, basada enb el peso de la base libre del ipamorelin; b) un exceso molar de ácido, preferiblemente ácido acético, en cantidad suficiente para dar un pH de por lo menos 3 y menos de 7; c) opcionalmente a partir de 0.1 al 30% de una o más ayudas de la formulación; y d) agua q.s. al 100% todos los porcentajes basados en el peso total de la solución.
CU20110232A 2009-06-12 2011-12-12 Inyección de diacetato de ipamorelin y soluciones de la infusión CU20110232A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18659509P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
CU20110232A7 true CU20110232A7 (es) 2012-06-21

Family

ID=42272260

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110232A CU20110232A7 (es) 2009-06-12 2011-12-12 Inyección de diacetato de ipamorelin y soluciones de la infusión

Country Status (24)

Country Link
US (1) US20100317581A1 (es)
EP (1) EP2440180B1 (es)
JP (1) JP2012529510A (es)
KR (1) KR20120030530A (es)
CN (1) CN102481251A (es)
AU (1) AU2010259102B2 (es)
BR (1) BRPI1012931A2 (es)
CA (1) CA2765233A1 (es)
CL (1) CL2011003131A1 (es)
CO (1) CO6470880A2 (es)
CR (1) CR20110618A (es)
CU (1) CU20110232A7 (es)
DO (1) DOP2011000383A (es)
EA (1) EA201270011A1 (es)
EC (1) ECSP11011516A (es)
GT (1) GT201100318A (es)
MX (1) MX2011013113A (es)
NI (1) NI201100212A (es)
NZ (1) NZ596641A (es)
PE (1) PE20121064A1 (es)
SG (1) SG176717A1 (es)
TW (1) TW201106961A (es)
UA (1) UA104762C2 (es)
WO (1) WO2010144265A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6193017B2 (ja) * 2013-06-28 2017-09-06 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
JP6562902B2 (ja) 2014-03-28 2019-08-21 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017423A1 (en) 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2375148A1 (en) * 1999-06-04 2000-12-14 Novo Nordisk A/S Compositions for the treatment of the catabolic state of prolonged critical illness
JP4874989B2 (ja) * 2004-11-22 2012-02-15 ノヴォ ノルディスク アー／エス 可溶性で安定なインスリン含有調合物
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
CA2709913A1 (en) * 2007-12-21 2009-07-02 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну

Also Published As

Publication number Publication date
CA2765233A1 (en) 2010-12-16
KR20120030530A (ko) 2012-03-28
WO2010144265A2 (en) 2010-12-16
CL2011003131A1 (es) 2012-08-17
EP2440180B1 (en) 2014-08-27
TW201106961A (en) 2011-03-01
BRPI1012931A2 (pt) 2018-01-30
GT201100318A (es) 2014-10-13
MX2011013113A (es) 2012-02-21
EP2440180A2 (en) 2012-04-18
EA201270011A1 (ru) 2012-05-30
UA104762C2 (ru) 2014-03-11
AU2010259102A1 (en) 2012-01-12
US20100317581A1 (en) 2010-12-16
CO6470880A2 (es) 2012-06-29
CN102481251A (zh) 2012-05-30
AU2010259102B2 (en) 2013-09-12
PE20121064A1 (es) 2012-09-03
ECSP11011516A (es) 2012-03-30
DOP2011000383A (es) 2012-05-31
CR20110618A (es) 2012-03-02
NZ596641A (en) 2013-12-20
WO2010144265A3 (en) 2011-11-24
NI201100212A (es) 2012-04-11
JP2012529510A (ja) 2012-11-22
SG176717A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
CY1119269T1 (el) Θεραπεια βλαβων που προκαλουνται απο ιους
PE20130396A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
UA105229C2 (uk) Фармацевтичний склад
AR081983A1 (es) Articulo de dosis unitaria soluble que comprende un polimero cationico
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
EA201201298A1 (ru) Фунгицидные композиции, содержащие фосфорастворимый микроорганизм и фунгицидно активное соединение
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
MY151295A (en) Pyrimidyl indoline compound
BR112014017169A8 (pt) máquina de bebidas com módulo removível
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
IN2012DN00765A (es)
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
AR086395A1 (es) Envase para el tratamiento de patologias
BRPI0916540B8 (pt) inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos
WO2014020405A8 (en) Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
CU20110232A7 (es) Inyección de diacetato de ipamorelin y soluciones de la infusión
CO6310996A2 (es) Composicion fungicida que contiene un compuesto de imidazol en combinación con polioxinas
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
JP2011093891A5 (es)
RU2010126053A (ru) Применение аналогов соматостатина при менингиоме
TR201105424A2 (tr) Çinko etken maddeli bir farmasötik formülasyon.
TR200806302A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik formülasyon.